slc7a6os Antibody

What is SLC7A6OS and what are its known functions?

SLC7A6OS is a protein of approximately 35 kDa that functions primarily as a probable RNA polymerase II nuclear localization protein . It shares functional similarities with yeast Iwr1 (Interacts with RNA polymerase II), which specifically binds RNA pol II, interacts with basal transcription machinery, and regulates transcription of specific genes . The protein is widely expressed across multiple tissue types and has been localized to both nuclear and cytoplasmic compartments .

SLC7A6OS plays critical roles in:

• Directing RNA polymerase II nuclear import

• Hematopoietic progenitor cell differentiation

• Protein transport processes

• Central nervous system development (as demonstrated in zebrafish models)

The gene encoding this protein is highly conserved across vertebrate species, suggesting fundamental biological importance. In humans, the canonical protein consists of 309 amino acids, while the zebrafish homolog comprises 326 amino acids with 46% identity to the human version .

What species-specific SLC7A6OS antibodies are currently available?

Several species-specific antibodies have been developed for SLC7A6OS research:

Human-specific:

• Rabbit polyclonal antibodies validated for western blotting (WB), immunocytochemistry (ICC), immunofluorescence (IF), and immunohistochemistry on paraffin sections (IHC-p)

• Mouse monoclonal antibodies for WB and ELISA applications

Mouse-specific:

• Rabbit polyclonal antibodies specifically validated for western blot applications

Zebrafish-specific:

• Rabbit polyclonal antibodies suitable for WB and ELISA techniques

Additional antibodies are available for other species including fish, and some manufacturers also offer recombinant antibodies . When selecting an antibody, researchers should verify the validation status for their specific application and species of interest.

What are recommended sample preparation techniques for SLC7A6OS antibody applications?

For Western Blot:

• Protein extraction should be performed using buffers containing protease inhibitors

• Human HEK-293T cells have been successfully used as positive controls for SLC7A6OS detection

• Loading approximately 20-30 μg of total protein per lane is recommended

• The predicted band size for human SLC7A6OS is approximately 35 kDa

For Immunohistochemistry:

• Formalin-fixed, paraffin-embedded (FFPE) tissues have been successfully used with SLC7A6OS antibodies

• Human testis tissue has been validated for IHC applications with SLC7A6OS antibodies at 1/500 dilution

• Antigen retrieval methods may improve staining results

For Immunofluorescence:

• U-2 OS cells have been successfully employed for immunocytochemistry/immunofluorescence applications

• Standard 4% paraformaldehyde fixation is typically suitable

How should I design knockdown experiments to study SLC7A6OS function?

Based on successful zebrafish studies, the following approach is recommended:

• Morpholino design:

  • Target splice junctions (e.g., exon1-intron1 boundary) for effective knockdown

  • Carefully titrate morpholino concentration to avoid toxic effects (6 ng/embryo was optimal in zebrafish studies)

  • Include appropriate controls:

    • Standard control morpholino as negative control

    • p53 morpholino to control for potential off-target effects

• Delivery method:

  • Microinjection into 1-2 cell stage embryos (for zebrafish)

  • Use dye tracers like rhodamine dextran to confirm successful injection

• Validation of knockdown:

  • Perform RT-PCR with gene-specific primers to confirm absence of functional transcript

  • Include housekeeping gene controls (e.g., β-actin)

• Rescue experiments:

  • Co-inject with synthetic SLC7A6OS mRNA to confirm specificity of observed phenotypes

  • This approach successfully rescued morphant phenotypes in zebrafish studies

When designing these experiments, careful consideration of developmental timing is essential, as SLC7A6OS has stage-specific expression patterns during embryogenesis .

What are the optimal conditions for SLC7A6OS antibody use in immunoblotting?

Based on validated protocols for SLC7A6OS antibody applications:

• Antibody dilution:

  • For western blot, use anti-SLC7A6OS antibody at approximately 0.4 μg/mL concentration

  • This typically corresponds to 1:500-1:1000 dilution depending on antibody stock concentration

• Sample preparation:

  • HEK-293T whole cell lysates provide reliable detection

  • Both native expression and overexpression systems can be used

  • Consider using SLC7A6OS-overexpressing cells with epitope tags (e.g., myc-DDK) as positive controls

• Detection system:

  • Standard HRP-conjugated secondary antibodies with enhanced chemiluminescence detection

  • Predicted molecular weight of human SLC7A6OS is 35 kDa

• Controls:

  • Use vector-only transfected cells as negative controls

  • Include blocking peptides to verify antibody specificity

For challenging applications, overexpression systems with tagged SLC7A6OS constructs can significantly enhance detection sensitivity and specificity.

How can I study SLC7A6OS expression patterns during development?

Based on successful zebrafish studies, the following methodological approach is recommended:

• Whole-mount in situ hybridization (WISH):

  • Generate antisense RNA probes targeting SLC7A6OS transcripts

  • Include sense probes as negative controls

  • Ensure probe does not cross-react with complementary genes

• Probe generation protocol:

  • Amplify specific regions by PCR using primers with RNA polymerase promoter sequences

  • Purify PCR products before in vitro transcription

  • Incorporate digoxigenin-labeled nucleotides during transcription

• Developmental timepoints to analyze:

  • Early cleavage stages (0.2 hpf, 1-2 cell stage) to detect maternal transcripts

  • Mid-blastula (3 hpf) and gastrulation stages (10 hpf)

  • Early and late somitogenesis (12-22 hpf)

  • Organogenesis stages (24-48 hpf)

This approach revealed that zebrafish SLC7A6OS is a maternal gene expressed throughout development, with stronger expression in the developing central nervous system, particularly in defined brain regions, spinal cord neurons, and other CNS structures at later stages .

What mechanisms underlie SLC7A6OS function in RNA polymerase II nuclear import?

The molecular mechanisms of SLC7A6OS in RNA polymerase II nuclear import can be investigated by considering its homology to yeast Iwr1:

• Structural interactions:

  • SLC7A6OS likely physically associates with RNA polymerase II subunits

  • The protein may serve as an adaptor between the polymerase and nuclear import machinery

  • Structure-function studies using deletion mutants could identify critical interaction domains

• Experimental approaches:

  • Co-immunoprecipitation with RNA polymerase II subunits

  • Analysis of nuclear vs. cytoplasmic fractionation of RNA polymerase II in SLC7A6OS-depleted cells

  • Live cell imaging of fluorescently tagged RNA polymerase II in the presence/absence of SLC7A6OS

• Relationship to transcription:

  • Since yeast Iwr1 interacts with basal transcription machinery and regulates specific genes, SLC7A6OS may similarly affect transcriptional programs

  • RNA-seq analysis of SLC7A6OS-depleted cells could identify regulated gene networks

Understanding these mechanisms is crucial as they connect SLC7A6OS to fundamental cellular processes involving gene expression and nuclear-cytoplasmic transport pathways.

How does SLC7A6OS contribute to CNS development and function?

Based on zebrafish knockdown studies, SLC7A6OS plays critical roles in CNS development:

• Specific neuroanatomical impacts:

  • Knockdown causes morphological defects at the midbrain-hindbrain interface

  • The midbrain, hindbrain, and cerebellum development are compromised in morphants

  • These defects persist throughout development

• Molecular markers affected:

  • Expression patterns of key neural development markers are altered in morphants:

    • pax2a: important for midbrain-hindbrain boundary formation

    • neurod: critical for neuronal differentiation

• Functional consequences:

  • Morphants display altered somite morphology

  • Embryos become partially or completely immotile at 28 hpf, suggesting neuromuscular defects

• Clinical relevance:

  • The SLC7A6OS gene has been associated with epilepsy in humans

  • The specific developmental role in CNS suggests potential involvement in other neurological disorders

These findings highlight the importance of SLC7A6OS in proper CNS development and function, particularly in the organization of brain regions and neuronal connectivity.

What is the evolutionary significance of SLC7A6OS conservation across species?

The high degree of conservation of SLC7A6OS across vertebrates suggests critical biological functions:

• Comparative homology:

  • Zebrafish SLC7A6OS shows 46% identity to human SLC7A6OS

  • The protein exhibits 14% identity to Saccharomyces cerevisiae Iwr1

  • Orthologs have been identified in mouse, rat, bovine, frog, chimpanzee, and chicken

• Functional conservation:

  • Despite sequence divergence, the fundamental role in RNA polymerase II nuclear import appears conserved from yeast to humans

  • This suggests involvement in deeply conserved transcriptional regulatory mechanisms

• Expression pattern conservation:

  • The preferential expression in developing CNS tissues appears conserved across vertebrates

  • This suggests evolutionarily preserved roles in neurogenesis and brain development

• Research implications:

  • Model organisms like zebrafish provide valuable insights applicable to human biology

  • Cross-species antibody reactivity may be limited due to sequence differences, necessitating species-specific reagents

The evolutionary conservation of SLC7A6OS highlights its fundamental importance in basic cellular processes related to transcription, making it a valuable subject for comparative functional studies.

How can I resolve weak or absent signal when using SLC7A6OS antibodies?

When faced with detection challenges using SLC7A6OS antibodies, consider these methodological solutions:

• For Western blotting:

  • Increase protein loading (up to 50 μg/lane)

  • Reduce antibody dilution (try 1:250-1:500)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use more sensitive detection systems (enhanced chemiluminescence plus or femto reagents)

  • Consider membrane transfer optimization (PVDF may provide better retention than nitrocellulose)

• For Immunohistochemistry:

  • Optimize antigen retrieval methods (try citrate buffer pH 6.0 or EDTA buffer pH 8.0)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal amplification systems (TSA, polymer detection)

  • Validate antibody on known positive control tissues (e.g., human testis)

• For all applications:

  • Verify sample quality (check for protein degradation)

  • Confirm target expression in your experimental system

  • Consider using overexpression systems as positive controls

  • Remember that endogenous expression levels may be low in some cell types

If detection remains challenging after optimization, consider alternative antibodies or detection methods like mass spectrometry-based approaches.

What controls are essential when validating SLC7A6OS antibodies for new applications?

Comprehensive validation requires multiple controls:

• Positive controls:

  • Tissues/cells with known SLC7A6OS expression (human testis for IHC, HEK-293T or U-2 OS cells for WB/ICC)

  • Overexpression systems with tagged SLC7A6OS constructs

  • Recombinant SLC7A6OS protein for western blot optimization

• Negative controls:

  • Primary antibody omission controls

  • Isotype controls (matched immunoglobulin class and concentration)

  • Knockdown/knockout samples (morpholino-treated or CRISPR-edited)

  • Pre-adsorption with immunizing peptide

• Specificity controls:

  • Peptide competition assays

  • Detection of expected band size (35 kDa for human)

  • Multiple antibodies targeting different epitopes

  • Parallel RNA expression analysis (qRT-PCR or RNA-seq)

• Application-specific controls:

  • For developmental studies: stage-specific expression patterns matching mRNA profiles

  • For cellular localization: fractionation controls or co-localization with known markers

Documentation of these validation steps is crucial for publication and reproducibility purposes.

How should discrepancies be interpreted between SLC7A6OS protein and RNA expression levels?

When investigating inconsistencies between protein and RNA levels:

• Potential biological explanations:

  • Post-transcriptional regulation (miRNAs, RNA-binding proteins)

  • Translational efficiency differences

  • Protein stability/half-life variations

  • Tissue-specific regulatory mechanisms

• Technical considerations:

  • Antibody specificity issues (verify with alternative detection methods)

  • Sensitivity differences between RNA and protein detection methods

  • Sample preparation artifacts (protein degradation during extraction)

  • Epitope masking (protein interactions or modifications affecting antibody binding)

• Methodological approach to resolution:

  • Employ multiple detection methods for both protein (different antibodies, mass spectrometry) and RNA (qRT-PCR, in situ hybridization)

  • Examine temporal dynamics (RNA changes may precede protein changes)

  • Investigate post-translational modifications using specific antibodies

  • Consider using tagged SLC7A6OS constructs to bypass antibody limitations

These discrepancies often reveal important biological regulation mechanisms rather than technical artifacts, so they should be carefully investigated rather than dismissed.

What is the relationship between SLC7A6OS function and neurological disorders?

The association between SLC7A6OS and epilepsy suggests important neurological implications:

• Functional connections:

  • SLC7A6OS critical role in CNS development observed in zebrafish

  • Disruption of normal brain development in morphants, particularly in midbrain-hindbrain boundaries

  • Potential impact on neural circuit formation relevant to seizure susceptibility

• Research approaches:

  • RNA-seq analysis of SLC7A6OS-depleted neuronal cells to identify dysregulated gene networks

  • Electrophysiological studies in model systems with altered SLC7A6OS expression

  • Patient-derived cells (e.g., iPSCs) from individuals with epilepsy to examine SLC7A6OS function

• Therapeutic implications:

  • Potential for SLC7A6OS as a biomarker for specific neurological conditions

  • Possibility of targeting SLC7A6OS-regulated pathways for intervention

Researchers investigating neurological disorders should consider SLC7A6OS expression analysis in affected tissues and examine potential mutations or expression alterations in patient cohorts.

How can SLC7A6OS expression patterns be used to elucidate developmental processes?

The dynamic expression pattern of SLC7A6OS during development provides valuable insights:

• Developmental markers:

  • Maternal expression (1-2 cell stage) indicates potential roles in earliest developmental events

  • Specific brain region expression (diencephalon, midbrain, hindbrain, cerebellum, telencephalon) at 24-48 hpf suggests region-specific functions

  • Expression in spinal cord neurons implies roles in neuronal specification or function

• Experimental applications:

  • Use SLC7A6OS antibodies as markers for specific developmental stages or regions

  • Correlate SLC7A6OS expression with other developmental markers (pax2a, neurod)

  • Track developmental abnormalities through altered SLC7A6OS expression patterns

• Methodological approaches:

  • Double immunostaining with SLC7A6OS antibodies and other developmental markers

  • Time-course analysis of expression throughout embryogenesis

  • Tissue-specific knockdown to examine regional requirements

These approaches can provide insights into both normal developmental processes and potential origins of neurodevelopmental disorders.

What are future directions for SLC7A6OS antibody development?

Several promising avenues exist for enhancing SLC7A6OS antibody tools:

• Technical improvements:

  • Development of phospho-specific antibodies to detect potential regulatory modifications

  • Generation of antibodies against specific isoforms or splice variants

  • Production of highly specific monoclonal antibodies for consistent performance

• Application expansions:

  • Validation for additional techniques (ChIP-seq, proximity labeling, super-resolution microscopy)

  • Development of antibodies suitable for in vivo imaging

  • Creation of directly conjugated antibodies for multiplexing applications

• Species coverage:

  • Expanded validation across additional model organisms

  • Creation of cross-reactive antibodies for comparative studies

  • Development of humanized antibodies for potential clinical applications

These advances would significantly enhance the research toolkit available for investigating SLC7A6OS biology across different experimental contexts.